Globus Medical (GMED)
(Delayed Data from NYSE)
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 4:44 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMED 73.43 +0.80(1.10%)
Will GMED be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMED
Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval
Globus Medical (GMED) Global Sales, Innovation Aid Growth
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
Other News for GMED
GMED Crosses Above Average Analyst Target
Buy Recommendation for Globus Medical Amidst Strategic Orthopedic Advances and Market Expansion
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
Globus Medical receives FDA 510k clearance for ExcelsiusFlex, ACTIFY
Globus Medical gets FDA approval for two knee replacement products